Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O60479
UPID:
DLX3_HUMAN
Alternative names:
-
Alternative UPACC:
O60479; B3KQL6
Background:
Homeobox protein DLX-3 plays a pivotal role in the development of the ventral forebrain, contributing to craniofacial patterning and morphogenesis. This protein's regulatory functions are crucial for proper facial development.
Therapeutic significance:
Homeobox protein DLX-3 is implicated in Trichodentoosseous syndrome and Amelogenesis imperfecta 4, diseases affecting dental and skeletal development. Targeting DLX-3 could lead to innovative treatments for these genetic disorders.